πŸ‡ΊπŸ‡Έ FDA
Patent

US 10844137

Anti-CTLA-4 antibodies and uses thereof

granted A61KA61K2039/507A61K2039/545

Quick answer

US patent 10844137 (Anti-CTLA-4 antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/507, A61K2039/545, A61K2300/00, A61K39/395